Abbott Laboratories (ABT) a biopharmaceutical major, announced on Wednesday that it has received FDA approval for its dual chamber (DR) leadless pacemaker system dubbed AVEIR.
As per the company, more than 80 percent of the people need a pacemaker pacing in two chambers of the heart and the approval increases the access leadless pacing for millions of people across the U.S.
Shorter, smaller, and slimmer than a AAA battery, the pacemaker is implanted directly into the heart's interior surface through a minimally invasive procedure which uses a screw in mechanism called the Helix.
The leadless pacemaker limits the patients' exposure to potential lead and infection-related complications and offers a less restrictive and shorter recovery period post-implantation.
These devices are around one-tenth the size of a traditional pacemaker and are made up of 2 devices. The previously-approved AVEIR VR single chamber device paces the right ventricle, and the now-approved AVEIR AR single chamber device paces the right atrium.
The AVEIR DR system incorporates Abbott's novel i2i technology, which offers beat-to-beat communication between the two leadless pacemakers.
Currently, shares of Abbott are trading at $107.57 up 0.32% on the New York Stock Exchange.
For comments and feedback contact: editorial@rttnews.com
Business News
April 17, 2026 15:29 ET The ongoing conflict in the Middle East continues to raise concerns for policymakers who worry about the impact of the supply shock and high energy prices on the real economy. Producer price data and various survey results on the housing market were the main news from the U.S. this week. In Europe, industrial production data for the euro area gained attention. GDP figures out of China and the policy move by the Singapore central bank were in focus in Asia.